- Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1
- CHMP opinion is based on two Phase III ASCLEPIOS studies that met the primary endpoints where Kesimpta showed a reduction of the annual relapses by over 50% versus teriflunomide and achieved more than 30% relative risk reduction of 3-month confirmed disability progression (CDP) 1
- In a post hoc analysis, nearly …
- First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine
- Initial agreement signed with BioNTech to use Novartis manufacturing plant in Stein, Switzerland, to support production of mRNA COVID-19 vaccine
- Production to commence in the second quarter for estimated delivery commencing in the third quarter 2021
Basel, January 29, 2021 — Novartis announced …
- Novartis leprosy medicine donation program with WHO extended to 2025
- Program has already treated over 7 million patients since 2000
- New evidence from contact tracing and preventive treatment program shows route to accelerate elimination
Basel, January 29, 2021 — A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 …
Media Releases
Download the media release
English (PDF 0.2 MB ) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)
Novartis ranked second in the 2021 Access to Medicine Index (ATMIndex), maintaining the same leading position as in 2018, in recognition of its long-standing efforts to improve …
- Full year net sales from continuing operations¹ up 3% (cc², +3% USD):
- Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris (+31% cc) and the Xiidra acquisition (+95% cc)
- Oncology BU grew 3% (cc) driven by Promacta/Revolade (+23% cc), Jakavi (+20% cc), Kisqali (+45% cc), Tafinlar + Mekinist (+16% cc) and Piqray (reaching USD 0.3 billion)
- Sandoz …
Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
- Full year net sales from continuing operations¹ up 3% (cc², +3% USD):
- Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris (+31% cc) and the Xiidra acquisition (+95% cc)
- Oncology BU grew 3% (cc) driven by Promacta/Revolade (+23% cc), Jakavi (+20% cc), Kisqali (+45% cc), Tafinlar + Mekinist (+16% cc) and Piqray (reaching USD 0.3 billion)
- Sandoz sales …
Sandoz officially certified as Global Top Employer 2021
- Top Employers Institute recognizes Sandoz for its exceptional employee offerings globally
- Third such annual certification for Sandoz underlines ongoing commitment to attract and keep best talent by building a great place to work
Basel, January 25, 2021 – Sandoz, a Novartis division, is pleased to announce that it has been officially awarded “Global Top Employer 2021” certification for the third year in a row. This year, Sandoz was one of only 16 Top Employers recognized for their outstanding HR …
COVID-19 was a catalyst for change in healthcare during 2020 – an accelerator for digital health.
2021 looks set to continue the revolution – exploiting ‘an explosion of interest, traction and scale’ in the potential for digital innovation to meet global healthcare needs.
In early 2020, as the virus spread exponentially, the world was forced to work virtually, where possible. Digital solutions were needed fast – not just to support remote-working, but to keep the very fabric of business, healthcare, education, and essential services in operation.
For Novartis and many …
- Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients
- Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years
- Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by March 1, 2021
Basel, January 19, 2021 — Novartis and GSK today announced the …